<DOC>
	<DOC>NCT02400788</DOC>
	<brief_summary>The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.</brief_summary>
	<brief_title>Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Main Patients with advanced or metastatic hepatocellular carcinoma Patients with ECOG PS of 01 Patients who can be treated with oral medications and have no gastrointestinal function disorder which is considered to affect the absorption of medications Main Patients with a history of treatment with HDAC inhibitors Pregnant women and lactating mothers Patients with brain metastases or suspected brain metastases based on the clinical symptoms</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>